4.450NOK-4.09%Mkt Cap: 1.60B NOKP/E: —Last update: 2026-06-01
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 200…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.60B NOK
Enterprise Value1.63B NOK
Revenue (TTM)839.00K NOK
Gross Profit839.00K NOK
Net Income (TTM)-58.00M NOK
Revenue/Share0.0030 NOK
Last Price4.450 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees18
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010597883
Valuation
P/E (Trailing)—
P/E (Forward)-42.18
PEG—
EV/EBITDA-32.59
EV/Revenue1947.25
P/S1990.95
P/B3.60
EPS (TTM)-0.17
EPS (Forward)-0.11
52W Range
2.29063% of range5.730
52W High5.730 NOK
52W Low2.290 NOK
Profitability
Gross Margin100.00%
Oper. Margin-4932.75%
EBITDA Margin0.00%
Profit Margin-14500.00%
ROE-12.72%
ROA-8.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.50M NOK
CapEx (TTM)73.10M NOK
FCF Margin-10787.05%
FCF Yield-5.65%
Net Debt-9.18M NOK
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity0.38
Current Ratio4.57
Quick Ratio4.46
Book Value/Sh1.288 NOK
Cash/Share0.5100 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.500 NOK
Target Range3.500 NOK – 3.500 NOK
# Analysts1
Ownership
Shares Out.360.00M
Float149.60M
Insiders41.21%
Institutions8.63%
Technical
SMA 504.704 (-5.4%)
SMA 2004.238 (+5.0%)
Beta-0.30
S&P 52W Chg27.70%
Avg Vol (30d)1.75M
Avg Vol (10d)1.13M
Technical Indicators
RSI (14)53.5
MACD-0.0388
MACD Signal-0.0722
MACD Hist.+0.0334
BB Upper4.640 NOK
BB Middle4.456 NOK
BB Lower4.273 NOK
BB Width8.24%
ATR (14)0.1948 NOK
Vol Ratio (20d)0.88x